Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition by Harris, P N A et al.
1 
 
Proposed primary endpoints for use in clinical trials that 
compare treatment options for bloodstream infection in 
adults: a consensus definition 
 
 
Authors: 
Patrick N.A. Harris1,2*, John F. McNamara1, David C. Lye3, Joshua S. Davis4,5, Louis 
Bernard6,  Allen C. Cheng7,8, Yohei Doi9, Vance G. Fowler Jr10, Keith S. Kaye11, 
Leonard Leibovici12, Jeffrey Lipman13,14, Martin J. Llewelyn15, Silvia Munoz-Price16, 
Mical Paul17, Anton Y. Peleg18,19, Jesús Rodríguez-Baño20, Benjamin A. Rogers19, 
Harald Seifert21,22, Visanu Thamlikitkul23, Guy Thwaites24,25, Steven Y. C. Tong4, 
John Turnidge26, Riccardo Utili27, Steven A. R. Webb28, David L. Paterson1,29 
1. University of Queensland, UQ Centre for Clinical Research, Brisbane, 
Australia 
2. Department of Microbiology, Pathology Queensland, Central Laboratory, 
Royal Brisbane & Women’s Hospital, Brisbane, Australia 
3. Institute of Infectious Disease and Epidemiology, Tan Tock Seng Hospital and 
Yong Loo Lin School of Medicine, Singapore 
4. Global and Tropical Health Division, Menzies School of Health Research,  
Darwin, Northern Territory, Australia 
5. Department of Infectious Diseases, John Hunter Hospital, Newcastle, 
Australia 
6. Infectious Diseases Unit, Tours University Hospital, France 
7. Department of Epidemiology and Preventive Medicine, Monash University, 
Victoria, Australia 
8. Department of Infectious Diseases, The Alfred Hospital and Central Clinical 
School, Monash University, Victoria, Australia 
2 
 
9. Division of Infectious Diseases, University of Pittsburgh School of Medicine, 
Pennsylvania, USA 
10. Duke University Medical Center and Duke Clinical Research Institute, 
Durham, North Carolina USA 
11. Wayne State University School of Medicine, Detroit Medical Center, Detroit, 
MI, USA  
12. Department of Medicine E, Beilinson Hospital, Rabin Medical Center, Petah-
Tiqva; and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 
Israel. 
13. Burns, Trauma and Critical Care Research Centre, The University of 
Queensland, Brisbane, QLD, Australia; Department of Intensive Care 
Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia. 
14. The University of Witwatersrand, South Africa 
15. Division of Medicine, Brighton and Sussex Medical School, UK 
16. Froedtert & Medical College of Wisconsin, USA 
17. Division of Infectious Diseases, Rambam Health Care Campus and The Ruth 
and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of 
Technology, Haifa, Israel 
18. Department of Microbiology, Monash University, Victoria, Australia 
 
19. School of Clinical Sciences, Monash Medical Centre, Monash University, 
Clayton, Victoria, Australia; Monash Infectious Diseases, Monash Health, 
Clayton, Victoria, Australia 
20. Unidad Clínica Intercentros de Enfermedades Infecciosas, Microbiología y 
Medicina Preventiva, Hospitales Universitarios Virgen Macarena y Virgen del 
3 
 
Rocío - IBiS and Departamento de Medicina, Universidad de Sevilla, Seville, 
Spain. 
21. German Centre for Infection Research (DZIF), Germany 
22. Institute for Medical Microbiology, Immunology and Hygiene, University of 
Cologne, Cologne, Germany 
23. Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand 
24. Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam 
25. Nuffield Department of Medicine, University of Oxford, United Kingdom 
26. Pathology, Paediatrics and Molecular Biosciences, University of Adelaide, 
South Australia, Australia 
27. Internal Medicine, Second University of Naples, Italy 
28. Royal Perth Hospital, and School of Medicine and Pharmacology, University 
of Western Australia, Perth 
29. Wesley Medical Research, Wesley Hospital, Toowong, QLD, Australia 
 
*Corresponding author: 
Dr Patrick Harris 
University of Queensland, UQ Centre for Clinical Research, Building 71/918, Royal 
Brisbane and Women's Hospital, Herston, QLD, 4029, Australia    
Mobile: +61 (0) 423785006 
Email: p.harris@uq.edu.au 
 
Word count: 3,624 
Keywords: Antibiotic therapy, clinical trials, treatment outcome, bacteraemia, 
bacterial infections 
4 
 
Running title: Primary Endpoints for bloodstream infection trials 
 
  
5 
 
Abstract 
No standardised endpoint definitions exist to aid the design of trials that compare 
antibiotic therapies for bloodstream infection (BSI).  We reviewed endpoints used in 
contemporary BSI studies and defined consensus endpoints using a modified Delphi 
process. Prospective studies, randomised trials or registered protocols comparing 
antibiotic therapies for BSI, published from 2005 to 2016, were reviewed.  Different 
primary and secondary endpoints were defined for pilot (small-scale studies designed 
to evaluate protocol design, feasibility and implementation) and definitive trials 
(larger-scale studies designed to test hypotheses and influence clinical practice), as 
well as for Staphylococcus aureus and Gram-negative BSI. For pilot studies of S. 
aureus BSI, a primary outcome of success at day 7 was defined by: survival, 
resolution of fever, stable/improved Sequential Organ Failure Assessment (SOFA) 
score and clearance of blood cultures, with no microbiologically-confirmed failure up 
to 90 days. For definitive S. aureus BSI studies, a primary outcome of success at 90 
days was defined by survival and no microbiologically-confirmed failure. For pilot 
studies of Gram-negative BSI, a primary outcome of success at day 7 was defined by: 
survival, resolution of fever and symptoms related to BSI source, stable or improved 
SOFA score and negative blood cultures. For definitive Gram-negative BSI studies, a 
primary outcome of survival at 90 days supported by a secondary outcome of success 
at day 7 (as previously defined) was agreed. These endpoints provide a framework to 
aid future trial design. Further work will be required to validate these endpoints with 
respect to patient-centered clinical outcomes.   
 
Introduction 
6 
 
Bloodstream infection (BSI) is common and potentially lethal. It has been estimated 
that nosocomial BSI account for 575,000-677,000 episodes and 79,000-94,000 deaths 
in the USA [1]. It is a frequent reason for consultation with infectious diseases (ID) 
physicians and clinical microbiologists [2, 3]. The U.S. Food and Drug 
Administration (FDA) has not approved a new antibiotic specifically for BSI since 
daptomycin in 2006. However, there is considerable interest among clinicians and 
pharmaceutical companies in studying different antibiotic choices for this infection.  
 
Defining clinically meaningful endpoints will lend greater credibility and validity to 
clinical trials on antibiotic treatment. There are no uniform primary endpoints to 
compare antibiotic options for BSI. Standardised endpoints would have the advantage 
of facilitating study comparison and reducing data heterogeneity in meta-analyses, as 
well as providing guidance to researchers when designing studies. The purpose of this 
article is to describe consensus BSI endpoint definitions for use in future clinical trials 
and to delineate further work needed in order to optimise these definitions. 
 
Methods 
 
Twenty-seven researchers from 11 different countries working in the field of clinical 
infectious diseases, microbiology, critical care medicine or biostatistics/trial design 
agreed to take part in a modified Delphi process [4] in order to develop consensus 
endpoint definitions for studies comparing antibiotic treatments for BSI. Six rounds of 
surveys were sent to each participant, with each round building on the results of 
previous rounds using a web-based survey tool (www.surveymonkey.com).  The 
details of the Delphi process are summarized in Table 1. When unanimous agreement 
amongst participants was not achieved for any particular question, the level of 
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agreement and pertinent comments of the participants were then distributed in the 
next survey round. In this way, consensus was sought. Agreement was defined by 
majority support (>60% agree) for each component of the definitions.  
 
Literature review 
In order to examine pre-defined endpoints currently used by researchers, we reviewed 
randomised controlled trials and prospective comparative studies assessing antibiotic 
treatment for adult patients with BSI caused Gram-negative bacilli or Staphylococcus 
aureus. We searched PubMed and Scopus for relevant studies using the terms 
“prospective”, “antibiotic” and “bacteremia” limited to clinical trial article types 
published between January 2005 and April 2016.  We included published trial 
protocols for actively recruiting BSI studies, by searching ClinicalTrials.gov. We 
excluded retrospective studies, studies where endpoints were not clearly pre-defined, 
studies that did not compare antibiotic therapies as a primary aim, those involving 
fungi or Gram-positive organisms other than S. aureus, duplicated studies or those 
published in languages other than English.   
 
Results 
Thirteen different endpoints have been used in contemporary BSI studies.  These 
endpoints are summarized in Table 2 (study details can be found in Supplementary 
Table 1).  The panel agreed that no well validated primary endpoints for the study of 
antibiotics in the treatment of BSI existed (Round 3: 17 agreed, 0 disagreed).  The 
majority of the panel felt that primary endpoints needed to be different for studies of 
BSI due to S. aureus vs. Gram-negative bacilli (Round 3: 16 agreed, 1 disagreed). 
This was due to the different spectrum of complications associated with BSI due to 
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Gram-negative bacilli as compared to S. aureus. The majority also felt that endpoints 
for pilot studies should differ compared to those for large definitive studies (Round 3: 
16 agreed, 1 disagreed). The panel agreed that trial endpoints should not be defined 
by deviation from the trial protocol (Round 4: 18 agreed, 1 disagreed). For example, 
starting a non-study antibiotic for a secondary infection, or failing to take protocol-
defined blood cultures, should not be regarded as clinical failure. 
 
Objective clinical outcomes 
The panel agreed that the most objective clinical outcome is mortality, and that it 
should always be measured as an outcome in trials of antibiotic treatment for BSI. 
While mortality as an outcome is clearly objective, differences exist as to when 
mortality should be measured and whether it should be attributed to the BSI as its 
primary cause.  
 
The panel considered the optimal timing for measuring this outcome. Once this time 
point is extended far beyond the initial BSI, mortality may become dominated by 
underlying disease. Mortality has been variably measured ‘in hospital’ or following 
discharge, with the timing of mortality determination occurring at 7, 14, 28-30 or 90 
days. Early mortality (e.g. 7-14 days) may be more specific for infection-related 
mortality, but may fail to capture delayed fatalities that could still be influenced by 
the BSI event. In the consensus definitions, early mortality (7 days) was used for pilot 
studies, and later mortality (90 days) for larger, definitive studies (Table 3).  
 
Despite the objectivity of mortality as an endpoint, the panel did not agree that 
mortality should be used as the sole primary outcome measure. Mortality as a sole 
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outcome may not capture other clinically relevant effects of different antibiotic 
regimens. The use of attributable mortality was not recommended given the 
uncertainty of attributing death to the BSI alone (Round 4: 15 agreed 4 disagreed). 
The panel concluded that mortality should be included as part of any primary 
endpoint, but should be accompanied by clinically relevant secondary endpoints. 
 
Other objective endpoints such as length of stay in hospital or rates of re-admission 
were considered by the panel, since they may reflect an important consideration from 
the point of view of a patient or the “payer” of a healthcare system. In critical care 
medicine, endpoints such as intensive care unit (ICU)-free days alive have been used 
[5]. There is likely to be a wide variability in length of hospital stay due to patient or 
clinician preference or institutional practices. In the absence of uniform standards for 
discharge from hospital following BSI, these outcomes were not included in the 
consensus primary endpoints.          
 
Subjective clinical outcomes 
Health related quality of life is important to patients. Unfortunately, it is difficult to 
get a reliable measure of pre-antibiotic quality of life since BSI is an unexpected 
event, although a measure of “functional status” (e.g. the Karnofsky score [6]) may be 
more readily determined pre-BSI. The panel concluded that such measures are clearly 
important for patients, but lack sufficiently robust measurements at the present time to 
permit their use as primary endpoints, but may be suitable for secondary endpoints.  
Several panel members suggested that patient-centred measures should be explored in 
future research and could be adapted from existing scoring systems.  Some commonly 
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used quality of life scores that may be applicable to BSI are summarised 
(Supplementary Table 2).  
 
Resolution of symptoms relevant to the BSI may be considered evidence of “clinical 
cure”. Even when used in conjunction with resolution of signs of abnormality on 
physical examination or radiologic investigations, some panel members expressed a 
view that assessment of “clinical cure” was too subjective to be used as a primary 
endpoint (although may be considered as a secondary endpoint). However, regulatory 
authorities such as the FDA or European Medicines Agency (EMA) currently 
recommend such clinical outcome measures, in conjunction with microbiological 
response, for registration trials of treatment for urinary tract infection [7, 8]. Given 
that BSI can represent a heterogeneous clinical entity, especially for Gram-negative 
organisms, including of a measure of subjective clinical response may be useful in 
comparing efficacy when the BSI may reflect a final common path for different 
infectious syndromes (e.g. urinary tract infection, pneumonia, catheter-associated 
infection). When used, standardised criteria should be employed and assessed by a 
blinded and independent clinical events committee.    
 
Microbiologic endpoints 
A potential microbiologic endpoint is clearance from the blood of the pathogen of 
interest. This has been used as a primary endpoint in a recent pilot study of antibiotic 
regimens for methicillin-resistant S. aureus (MRSA) BSI [9], and as a secondary 
endpoint in a trial evaluating continuous infusion of beta-lactam antibiotics [5]. The 
panel considered that this endpoint is less relevant for Gram-negative BSI, where 
prolonged bacteraemia is uncommon [10] and much less frequent than for S. aureus 
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[11]. Breakthrough infections may be of relevance for some Gram-negative BSIs, 
such as AmpC-hyperproducing variants of Enterobacter cloacae [12].  
 
The panel agreed that relapse of BSI or recurrence of infection at a distant site was an 
important endpoint for S. aureus BSI. This endpoint should always be used in 
conjunction with clinical endpoints. Furthermore, recurrence of infection at a distant 
site may not always be amenable to microbiological confirmation by culture (e.g. 
vertebral osteomyelitis), and some panel members expressed a view that this may be 
better defined as a clinical endpoint. However, given the lack of specificity in 
determining microbiological failure without culture confirmation, the consensus 
endpoints require culture of S. aureus from sterile sites to define failure (Table 3). 
The optimal duration of follow-up required to capture these events is uncertain. 
However, the great majority of cases relapse within 6 weeks of initial BSI [13, 14].   
 
An additional area of uncertainty is defining the optimal clinical samples to include in 
the follow-up period to determine microbiological failure.  For BSI studies it may be 
important to discriminate between persistent and relapsed BSI by including 
stipulation for collection of ‘clearance’ blood cultures. A protocol that requires 
frequent additional blood sampling may also suffer from limited adherence and 
consequent missing data. Furthermore, relapse of infection at distant sites (e.g. bone 
and joint infection) would need to be captured by also including sterile site 
specimens. Inclusion of non-sterile samples (e.g. sputum, urine) would be less 
specific for true microbiological relapse. Appropriate molecular typing methods 
should be applied to discriminate between re-infection and relapse.   
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Surrogate endpoints 
Surrogate endpoints have been used extensively in clinical trials within other areas of 
infectious disease (e.g. HIV viral load [15]). For trials comparing treatment for BSI, 
investigators could potentially measure response to therapy either by using relevant 
biomarkers (e.g. C-reactive protein, procalcitonin) or clinical parameters (e.g. an 
illness severity score).  
 
The panel considered what attributes would constitute a useful surrogate marker in the 
context of BSI. Practical definitions of a meaningful surrogate marker are available 
(see Panel 1, supplementary data) [16]. Essentially, a surrogate must capture any 
relationship between the treatment and the true endpoint of interest.  The panel 
expressed the view that while the use of surrogate outcomes has potential advantages, 
great care needs to be taken in the selection and validation of the surrogate outcome.  
 
The panel considered the role of measuring resolution of clinical features of infection 
(e.g. fever, tachycardia, white cell count) as a surrogate endpoint. However, it was 
agreed that these markers could not be used as a sole primary endpoint, given that so 
many variables other than antibiotic activity may have an influence. There was 
interest in using the Sequential Organ Failure Assessment (SOFA) score, which 
captures information on respiratory, cardiovascular, hepatic, coagulation, renal and 
neurological systems [17] and can be used to assess daily changes in a patient’s status 
within the ICU. This is an advantage over APACHE [18] or SAPS [19], which predict 
mortality based on the first 24 hours of observation. However, SOFA requires 
measurements that are only generally applicable in ICU, such as arterial blood gas 
analysis.  A modified SOFA score may be more applicable to general ward patients 
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[20]. Other scoring systems of disease severity that may be applicable in BSI studies 
were discussed and are summarised in Supplementary Table 3.   
 
The consensus panel universally agreed that no reliable or well-validated surrogate 
endpoint for mortality currently exists to use in BSI trials (Round 3: agreed 17, 
disagreed 0). They may have greater applicability in phase II trials or be used as part 
of secondary outcome measures in phase III trials.  
 
Composite endpoints 
Composite endpoints can enhance the power of a clinical trial and capture a wider 
spectrum of clinically relevant events and increase the expected event rate.  However, 
several members of the panel expressed caution. The frequency of combined events 
may not occur in the same direction cancelling-out an overall effect. Furthermore, one 
component of the combined outcome may be more clinically important than another, 
and significant differences may be driven by less serious outcomes. As such, each 
component of a composite outcome should be reported separately to assess the 
direction and size of each effect. If more than one primary endpoint is used, the 
chance of obtaining a significant result by chance alone is also increased. Appropriate 
weighting of components of greater significance is essential but the panel could not 
find examples where they were used in trials of BSI. 
 
The panel considered composite endpoints used or proposed in trials of S. aureus BSI. 
The endpoints used in a published randomised controlled trial (RCT) of daptomycin 
vs. vancomycin for treatment of BSI, which used a primary outcome of clinical 
success at 42 days (with failure defined by clinical and microbiological factors as well 
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as protocol violations) [21] came under criticism. Concerns included failure defined 
by starting a non-study antibiotic for a secondary infection, or failing to take protocol 
blood cultures. The primary endpoints used by the ARREST [22] (co-primary 
outcome of all-cause mortality up to 14 days from randomisation and bacteriological 
failure/all-cause mortality up to 12 weeks) or CAMERA [9]  (composite primary 
endpoint at 90 days of all-cause mortality, persistent bacteraemia at day 5 or beyond, 
microbiological relapse, or microbiological treatment failure) studies were felt to be 
more appropriate, although consensus could not be reached as to which endpoint was 
superior.  
 
New composite endpoints for BSI caused by S. aureus and for Gram-negative 
organisms with a >10% risk of mortality (e.g. E. coli) were determined by consensus 
(Table 3) (Round 5: S. aureus, 15 agreed, 3 disagreed; Gram-negatives, 14 agreed, 4 
disagreed). Unanimous agreement was not reached on the components of these 
composite primary endpoints. The advantages and disadvantages of the various 
primary endpoints discussed by the panel are summarized in Table 4.  
 
Ordinal Scales  
The panel considered the use of a desirability of outcome ranking (DOOR) score as 
described by Evans and colleagues [23].  Our panel was not able to reach consensus 
on this topic (Table 1) (Round 6: 10 Agree, 9 disagreed). The perceived advantages 
and disadvantages of a desirability of outcome scale by our panel are summarised in 
Table 4. 
 
Discussion 
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BSI is a common condition encountered by ID physicians and clinical 
microbiologists, yet many questions remain as to its optimal management. In a recent 
survey, ID physicians were asked to rank proposals for RCTs in terms of which were 
most likely to change their practice. Five of the ten top-ranking RCT proposals were 
related to BSI due to S. aureus, Enterococcus or multiresistant Gram-negative 
pathogens [3]. Seventeen investigator-initiated RCTs on antibiotic therapy for BSI are 
currently registered as recruiting patients (clinicaltrials.gov, accessed on 16th April, 
2016). Despite this research activity, there is no generally accepted primary endpoint 
for these studies [24]. Some regulatory guidance for endpoint selection in therapeutic 
trials is available for certain infectious disease indications from the FDA [8, 25] but 
they do not directly address BSI studies [24]. The EMA guidelines recommend the 
use of a clinical outcome (defined as cure, failure or indeterminate) measured at a 
fixed number of days post randomisation according to pre-determined definitions, 
with microbiological cure as a co-primary endpoint should this be of equal 
importance (e.g. in endocarditis) [7, 24]. One key issue identified by the panel was 
that endpoints required by regulatory authorities may be different from pragmatic 
investigator-initiated trials where, for instance, established agents or strategies are 
compared. These differences are summarized in Table 5.  The endpoints presented 
here are not intended to replace guidance from regulatory bodies, where the purpose 
is to gain approval for a novel drug or therapeutic intervention. We hope that future 
management of patients with BSI will be guided by research addressing questions 
routinely faced by clinicians. These studies are likely to be pragmatic, often 
investigator-initiated, perhaps involving optimisation of existing drugs or treatment 
strategies, and closely reflecting ‘real-world’ dilemmas.   
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One issue that has been previously considered by regulatory agencies is whether BSI 
should be considered as a separate clinical entity without reference to the likely 
source of infection.[26] The EMA and FDA have previously suggested that approving 
an indication for BSI without reference to the underlying cause is problematic, since 
this may imply efficacy regardless of the primary focus of infection.[26, 27] This may 
be most important for Gram-negative BSI, which is a heterogeneous condition, 
reflecting several possible clinical syndromes. For S. aureus BSI, ‘uncomplicated’ 
infections (such as vascular catheter-associated BSI with prompt line removal and no 
metastatic focus) represent a different spectrum of disease from endocarditis, 
vertebral osteomyelitis or primary BSI with unknown focus.     
 
BSI may not always be a useful target for new drug in development seeking a labelled 
indication, but for pragmatic investigator-initiated studies BSI is a highly relevant 
entity. BSI is common, is usually clinically unambiguous (at least for S. aureus and 
pathogenic Gram-negative bacilli), is associated with considerable morbidity and 
mortality and is easily detected in the laboratory. Furthermore, the presence of BSI 
requires decision-making in response to a clinical entity for which rigorous evidence 
is frequently lacking. Therefore, we believe that the application of standardised 
endpoints in the study of BSI is meaningful, even if it may reflect a heterogeneous 
group of clinical phenomena. 
 
A number of clear differences in opinion amongst the panel were present. A 
philosophical divide existed between panel members who felt that only patient-
centred outcomes (how a person feels, functions or survives) should be used for 
primary endpoints in large, pragmatic, practice-defining trials. This implies that only 
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mortality or a measure of disability as a result of the BSI should be used as a primary 
endpoint. In other words, prolonged bacteraemia or other indicators of microbiologic 
failure are irrelevant to any given patient. The alternate philosophic viewpoint is that 
markers of antibiotic activity include microbiologic response, as well as clinical 
response, and that evidence about this response has an important influence on whether 
a physician will choose any particular antibiotic regimen.  
 
The recent proposal by Evans and colleagues of the DOOR concept [23] provides a 
potential methodology to address non-inferiority and integrate patient centred 
outcomes and mortality along with appropriately validated surrogates. It also has the 
potential to provide a single scale for both pilot and definitive studies. Given the 
novel nature of the methodology, it was raised with the panel for discussion. Our 
panel were divided regarding the utility of this methodology. A commonly raised 
concern was its complexity, leading to uncertainty in how to interpret results and the 
potential for introducing bias.  When a smaller number of categories are used in a 
DOOR scale or if most patients fall into a small number of categories, this may 
increase power, raising the possibility that category definitions could be manipulated 
to increase the likelihood of demonstrating superiority [28]. A DOOR score requires 
consensus in terms of the components of the ordinal scale, and it is not yet clear how 
these should be defined. Endpoints can be ranked in order of importance in their 
assessment of comparative antibiotic activity. For example, in an assessment of S. 
aureus BSI, mortality may be ranked highest, followed by relapse of infection 
requiring open surgery, relapse after treatment is completed, slowness in fever settling 
and delay in clearance of bacteremia. Adverse events could also be incorporated into 
the rankings. A potential advantage of such an approach is that it is generally 
18 
 
congruent with physician assessment of the consequences of S. aureus BSI. Whether 
this approach is also congruent with a patient’s experience remains to be determined.  
 
Future research could address some of these uncertainties by using existing or 
prospectively collected data.  Such studies would require definition of ‘true’ 
outcomes, incorporating patient-centred variables (which may benefit from the input 
of patients themselves) and measures that are often overlooked, such as quality of life 
assessment.  Early surrogate measures of “success” could then be validated against 
these ‘true’ outcomes.  Given that increased mortality following sepsis can be 
demonstrated for up to 2 years post event [29] such validation studies may require 
follow-up beyond the usual 30 or 90 days. Once ‘true’ outcomes have been 
established in observational studies, a proposed ordinal scale could be formulated and 
validated for the use in clinical trials. The optimal time point for determining primary 
outcomes remains to be determined and further research is warranted to address this 
uncertainty.   
 
It is also important that studies comparing treatment for BSI ensure that other 
evidence-based approaches known to influence clinical outcomes (such as seeking 
and addressing a removal source of infection or ID consultation for S. aureus BSI 
[30]), are applied consistently between arms and compliance recorded.  
 
Limitations of these consensus endpoints are acknowledged.  Universal agreement 
was not achieved for all components of the definitions, and not all participants 
contributed towards every round. The definitions are largely derived from expert 
opinion where clinical evidence is sparse.  Even for questions where consensus was 
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achieved, this does not ensure that the chosen approach is without pitfalls. For 
instance, it was strongly agreed that endpoints should be defined differently between 
pilot and definitive studies. However, a contrary view might be that endpoints should 
be consistent between all phases of a clinical trial. This may be of concern when 
testing multiple early phase drug treatments for efficacy and safety signals, which 
could lead a significant ‘false discovery’ rate.[31] When testing multiple hypotheses 
(especially using a traditional p value criterion of <0.05 for significance), a ‘positive’ 
early phase trial may represent a statistical anomaly that fails to translate into a 
significant effect in later phase trials. It is unlikely that a ‘perfect’ set of endpoints can 
be currently defined, but this work can provide a basis for future evidence-based 
refinement.  
 
In conclusion, we have proposed primary endpoints that could be used in future 
observational and interventional studies of antibiotics for BSI. It is also hoped that 
this manuscript will stimulate further research into which endpoints are most likely to 
enhance antibiotic prescribing practices and improve patient outcomes. 
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Table 1: Summary of the Delphi process  
 
Round Themes / Questions 
 
Participants 
1 • Determination of appropriate questions to be included in 
the process 
19 
2 • Whether different endpoints required for GN / GP BSI 
• Whether different endpoints required for early phase / 
late phase trials 
• Whether patient-centred or clinical / microbiological 
outcomes should be preferred as a primary endpoint  
24 
3 • Agreement sought on requirement for different GN / GP 
endpoints 
• Agreement sought on requirement for different early 
phase / late phase endpoints 
• Strengths and weaknesses of endpoints used in previous 
trials discussed with specific examples 
• Timing of endpoint determination discussed 
• Utility of laboratory values (e.g. CRP, Procalcitonin, 
WCC), clinical variables (e.g. fever, symptom resolution) 
and microbiological tests (e.g. blood cultures) in 
endpoints discussed 
• Use of other quality of life measures in endpoints 
17 
4 • Agreement sought on whether protocol violations should 
be avoided as part of primary endpoints 
• Agreement sought on whether mortality attributable to 
BSI should be avoided for use in endpoints in preference 
to all-cause mortality 
• Agreement sought on best specific measures to include in 
primary and secondary endpoints, including the potential 
role for surrogate markers 
• Voting on proposed endpoints definitions with comments 
sought 
19 
5 • Voting on consensus definitions for primary and 
secondary endpoints in therapeutic trials for BSI caused 
by S. aureus and GN organisms 
18 
6 • Voting on applicability of a desirability of outcome 
ranking (DOOR) score for BSI 
19 
 
GN = Gram negative, GP = Gram positive, BSI = Bloodstream infection, CRP = C-
reactive protein, WCC = white cell count 
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Table 2: Endpoints used in RCTs and prospective observational studies of BSI 
published Jan 2005 – Apr 2016 [5, 21, 22, 32-51] 
  
Category Specific End Pointa Number of studies using each endpoint 
Primary Secondary Combined frequency 
of endpoint 
Objective clinical outcome 
  Mortality       
  In-hospital mortality 3 2 5 
 7 days 1 0 1 
  14 days 4 1 5 
  21 days 1 0 1 
  28 days 3 1 4 
  30 days 3 0 3 
 42 days 0 1 1 
 60 days 1 0 1 
  90 days 4 3 7 
  12 weeks 1 0 1 
 Clinical outcome other than mortality  
  ICU free days at 28 days 1 0 1 
  Duration of fever 0 4 4 
 Duration of antibiotic therapy 1 3 4 
  Organ failure free days 0 1 1 
  Clinical cure/response to treatment 7 6 13 
 Length of hospital stay post BSI 0 2 2 
 
Development of antibiotic 
resistance 0 3 3 
Subjective clinical measures  
  
Measures of functional status/ 
QOL indicators 0 2 2 
  Attributable mortality  1 2 3 
Microbiological outcome  
  
Bacteriological cure (Incorporating 
clearance of blood cultures) 5 10 15 
 Clostridium difficile diarrhoea 0 4 4 
Surrogate endpoints       
  Decrease in CRP 0 1 1 
 Procalcitonin level 0 1 1 
  
Markers of severity of 
inflammation 0 1 1 
 
Resolution of inflammatory 
response 1 3 4 
Cost   0 2 2 
Safety   1 11 12 
a When not specifically defined we inferred primary and secondary endpoints
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Table 3: Consensus definitions for BSI studies 
 
 
Staphylococcus aureus BSI Gram-negative BSI (including organisms 
associated with >10% mortality, e.g. E. coli) 
 
Pilot trial to select an intervention for a larger definitive trial 
 
Primary outcome: 
Success is defined by all of the following criteria 
being met at 7 days after randomization: 
1. Patient alive 
2. Fever resolved  
3. Stable or improved SOFAa score (compared to 
baseline) 
4. Blood cultures negative for S. aureus 
 
In addition: 
No isolation of S. aureus in blood cultures or 
another sterile site from 8 to 90 days after 
randomisation 
 
Primary outcome: 
Success would be defined at 7 days from 
randomization by all of the following: 
1. Patient alive 
2. Fever resolved 
3. Symptoms attributed to the focus of infection 
have resolved 
4. SOFAa score stable or improved  
5. Negative blood cultures in days 3-7 post 
randomisationb 
 
Definitive antibiotic trial, in a pragmatic 300+ patient investigator-initiated study, the purpose of 
which is to influence clinical practice 
 
Primary outcome: 
Success of therapy is defined at 90 days by 
presence of all of the following: 
 
1. Patient alive 
2. No evidence of microbiologically confirmed 
treatment failure, defined as either: 
(a) Persistence of S. aureus BSI more than 7 days  
(b) Isolation of S. aureus from a sterile site 
(blood, joint fluid, tissue) more than 14 days from 
randomisation 
 
Primary outcome:  
Patient alive at 90 days after randomization 
 
Composite secondary outcome: 
Success would be defined at 7 days from 
randomization by all of the following: 
1. Patient alive 
2. Fever resolved 
3. Symptoms attributed to the focus of infection 
have resolved 
4. SOFAa score stable or improved  
5. Negative blood cultures in days 3-7 post 
randomisationb 
 
a. can use modified SOFA if outside ICU 
b. taken only if the patient is febrile >=38°C, to prevent unnecessary additional protocol-driven blood 
collection 
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Table 4. Advantages and disadvantages of different primary endpoints for studies of 
antibiotics in treatment of BSI. 
 
  End Point Advantages Disadvantages 
 
1. Objective clinical outcomes 
  
  All-cause 
mortality 
Hard clinical outcome, highly 
objective, important to patients, 
accurate and simple to collect 
Large sample size generally required to demonstrate 
difference 
      Contentious as to ideal time of collection which leads 
to heterogeneity in end points 
      Fails to assess other patient centred end points such as 
improvements in quality of life 
 
2. Subjective clinical outcomes 
  
 Attributable 
mortality 
Highly relevant in elderly population 
and patients with multiple co 
morbidities 
Limited objectivity as open to interpretation, and 
mortality cannot reliably be attributed to BSI in 
isolation  
  Quality of life / 
Functional 
Status 
Patient centred outcome Lack of standardisation may lead to outcome 
measures which are not reproducible, requires 
measurement at baseline, requires consensus in the 
application of robust standardised measures. May 
require administration of complex questionnaires. 
  Resolution of 
symptoms 
In combination with clinical signs 
provides the end point of clinical cure 
- may require smaller sample size to 
demonstrate differences in efficacy, 
forms part of daily clinical practice 
Interpretation of symptoms remains a subjective 
measure, may not be suitable as an endpoint in 
isolation 
 
3. Microbiological outcomes 
  
  Clearance of 
the pathogen of 
interest 
Objective measure, highly relevant 
for S. aureus and some Gram-
negative organisms, simple to assess 
Not relevant for all pathogens, requires timely 
recollection of blood cultures 
 Clostridium 
difficile 
diarrhoea 
Objective measure  Large sample size to demonstrate difference; variation 
in laboratory testing methodology 
 Colonisation 
with multi-
resistant 
organisms  
Objective measure 
 
 
 
Requires additional sampling, variable laboratory 
methods and test sensitivity 
 
 
 Microbiome / 
resistome 
effects 
Objective measure of ‘collateral 
damage’ from antibiotics 
Limited experience in the use of metagenomic data as 
an outcome variable in clinical trials; unclear which 
measures best compare outcomes between treatment 
groups 
 
4. Surrogate endpoints 
  
  Biomarkers Improve power and/or practicality of 
trial 
Must be demonstrated to be a suitable substitute for 
clinically meaningful end point 
      No reliable or well-validated surrogate endpoint for 
mortality currently exists for mortality in BSI 
 Systemic 
inflammatory 
response 
syndrome 
Measured as part of daily clinical 
practice. Smaller sample sizes to 
demonstrate efficacy. Easily collected 
Response of these variables or lack of response may 
not be attributable to antibiotic alone; have never been 
validated in this context 
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5. Composite endpoints 
  
  Combined Improve power of study May be difficult to interpret if endpoints demonstrate 
co-linearity 
  Propensity 
Score / 
Ranked 
Improve power of the study, 
outcomes; may be graded 
Complex statistical analysis, clinicians less familiar 
with interpretation 
 
6. Desirability of outcome ranking (DOOR) score 
 
  Potential to provide a unified scale 
for all bloodstream studies and 
different pathogens 
Complexity of assigning and implement a scale with 
correctly weighted ranks 
Complexity of analysis 
 
  Capacity to improve the power of the 
study to detect superiority of 
treatment rather than non-inferiority 
May obscure non-inferiority or introduce bias. 
Difficulty in achieving consensus on components of 
the DOOR scale 
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Table 5 Differences between endpoint requirements for drug registration studies and pragmatic investigator-initiated trials  
 
  
Endpoint requirements for drug registration Endpoint requirements for pragmatic 
investigator-initiated trials 
Primary endpoint often involves clinical and 
microbiological response at an early stage (e.g. 
resolution of symptoms with microbiological 
clearance) 
 
Primary endpoint needs to reflect patient-centered 
outcomes  
Secondary endpoints often involve primary 
outcome measures assessed at a delayed time 
period (e.g. 28 days)  
 
Secondary endpoints often assess a range of other 
clinical outcomes, may be pathogen specific (e.g. 
S. aureus) 
May involve more laboratory testing (e.g. 
microbiological test of cure) as part of endpoints 
 
Often aim to keep additional laboratory testing to 
a minimum to curb costs and limit any patient 
burden beyond normal clinical care 
Purpose of the study is to assess efficacy and 
safety to enable registration of the product for 
market 
 
Purpose of the study is to optimise existing 
therapeutic strategies and inform clinical practice 
Study targets regulatory bodies (e.g FDA, EMA) 
 
Study targets clinicians 
 
